In Q1 2023, Redmile Group held 51 positions worth $1.8B. They initiated 51 new positions. Their largest holding was FOLD ($203.5M).
Frequently asked questions
What stocks did Redmile Group own in Q1 2023?
Redmile Group held 51 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include FOLD, KRYS, DCPH, AKRO, PLRX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Redmile Group's portfolio worth in Q1 2023?
Redmile Group's tracked biotech portfolio was worth $1.8B across 51 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Redmile Group buy in Q1 2023?
Redmile Group initiated 51 new positions in Q1 2023, including FOLD, KRYS, DCPH, AKRO, PLRX and 46 more. They also increased 0 existing positions.
What did Redmile Group sell in Q1 2023?
Redmile Group did not fully exit any positions in Q1 2023.
Is Redmile Group a biotech fund?
Healthcare crossover fund investing from late-stage private rounds through public equity. Redmile manages a diversified book across biotech, medtech, and healthcare services, with a reputation for backing management teams through multiple rounds of financing.
Want AI analysis, insider signals, and catalyst overlays for Redmile Group?
View latest Redmile Group portfolio →